News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Dendreon Corporation (DNDN) Announces Presentation Of PROVENGE┬« (sipuleucel-T) Data At The 2014 Genitourinary Cancer Symposium (ASCO GU)


1/30/2014 8:58:55 AM

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

Dendreon Corporation (NASDAQ:DNDN) today announced the presentation of four PROVENGE® (sipuleucel-T) abstracts and one abstract for DN24-02, an investigational active cellular immunotherapy, from ongoing clinical trials at the 2014 Genitourinary Cancers Symposium (ASCO GU) from January 30-February 1, 2014 in San Francisco, California.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES